Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 5/20 | 0.57 |
| ▸ | CA2 | P00918 | 5/20 | 0.57 |
| ▸ | KIF11 | P52732 | 4/20 | 0.56 |
| ▸ | PEPD | P12955 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7835389 | 1.00 | NPC1 (0.59) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL3893567 | 0.82 | CA1 (0.59) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL358576 | 0.82 | CA1 (0.80) | CA1CA2KMT2AMEN1CA12 | |
| SCHEMBL8247039 | 0.82 | ALDH1A1 (0.48) | CA1CA2ALDH1A1KMT2AMEN1 | |
| SCHEMBL27713763 | 0.81 | CA1 (0.63) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL28865482 | 0.80 | CA1 (0.67) | CA1CA2ALDH1A1KMT2AMAPT | |
| SCHEMBL3893214 | 0.80 | CA1 (0.57) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL11594813 | 0.80 | CA1 (0.57) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL3893212 | 0.80 | CA1 (0.57) | NPC1CA1CA2KIF11PEPD | |
| SCHEMBL58191 | 0.80 | CA1 (0.67) | CA1CA2ALDH1A1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | SHIFA BIOMEDICAL CORPORATION (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORP (US) | 2018-03-22 | — | — | US | disclosed |
| EP-2968318-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | Shifa Biomedical Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-31 | — | — | US | disclosed |
| WO-2014150395-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | SHIFA BIOMEDICAL CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-8586748-B2 | 2-sulfonylamino-4-heteroaryl butyramide antagonists of CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2276731-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | Boehringer Ingelheim International GmbH (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2009126675-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| EP-1670770-B1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1673369-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| EP-1670770-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | AstraZeneca AB (SE) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006033632-A1 | Benzimidazole derivatives and their use as cannabinoid receptor ligands I | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
| WO-2005030761-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| WO-2005030733-A1 | BENZIMIDAZOLE DERIVATIVES, COMPOSITIONS CONTAINING THEM, PREPARATION THEROF AND USES THEREOF | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
| US-6559167-B1 | Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under | REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-05-06 | — | — | US | disclosed |
| EP-1105387-B1 | PRODRUGS OF PROTON PUMP INHIBITORS | WINSTON PHARMATEUTICALS LLC (US) | 2003-01-29 | — | — | EP | disclosed |
| CN-1312806-A | Prodrugs of proton pump inhibitors | PARTNERSHIP OF MICHAEL E GAST (US) | 2001-09-12 | — | — | CN | disclosed |
| EP-1105387-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | Partnership of Michael E. Garst, George Sachs and Jai Moo Shin (US) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009498-A1 | PRODRUGS OF PROTON PUMP INHIBITORS | PARTNERSHIP OF MICHAEL E. GARST, GEORGE SACHS AND JAI MOO SHIN (US) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079730-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | NPC1 53/4885CA1 4665/4885CA2 4528/4885 |
| US-10131637-B2 | Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases | PCSK9, PCSK7, PCSK6 | NPC1 96/4885CA1 3997/4885CA2 2922/4885 |
| US-20150376139-A1 | ANTI-PCSK9 COMPOUNDS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF CARDIOVASCULAR DISEASES | PCSK9, PCSK7, PCSK6 | NPC1 53/4885CA1 4665/4885CA2 4528/4885 |
| US-20110275800-A1 | 2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10 | CCR10, CCR1, CCR4 | NPC1 612/4885CA1 4364/4885CA2 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.